Pharmaceutical research and development "catch up"?

The pharmaceutical industry is an industry that has been "named" many times in the "14th Five-Year" development plan.

Everyone knows the dangers of this industry.

"Global statistics show that the success rate of new drug research and development has dropped from 10% to the current 2%-3%.

Under such circumstances, the industry favors follow-up innovation with low risk.

The rush of R&D resources to follow innovation has made the "supply-side" contradiction in my country's pharmaceutical field prominent: high-end good drugs and new drugs are seriously insufficient, while low-end generic drugs are surplus.

To drive the pharmaceutical industry to actively move towards true innovation, it is necessary to allow scientific research institutes and pharmaceutical companies to solve the pain points in the process of new drug research and development, and allow innovative entities to taste the "sweetness" of original innovation.

The failure of effectiveness clinical trials is the main reason for the failure of new drug development, and the industry vividly calls it the "valley of death.

The program design and population selection of the current clinical trials are still blind.

In other words, you can find the answer by reading all the documents, but this work cannot be done by manpower alone.

"Last year alone, the number of papers related to the new crown virus that can be retrieved has increased from 0 to 110,000.

Artificial intelligence based on supercomputers can do it.

How does this platform work? For example, by analyzing the patient’s exon genetic data, etc.

Through the judgment of artificial intelligence, it is possible to find specific groups of people whose drugs are effective.

During the COVID-19 pandemic, the drug research and development AI born from China Supercomputing discovered that two drugs are effective for the treatment of COVID-19, and both were confirmed by clinical studies.

If the new drug-applicable population can be subdivided in phase 3 clinical trials, the "valley of death" of effectiveness verification will no longer be difficult.
The artificial intelligence supported by supercomputers can now provide more than 400 functional models to solve various problems in the development of innovative drugs, such as target prediction, active ingredient screening, and clinical trial effect prediction.
The research and development time is halved, the investment is halved, the success rate is doubled, and the effective rate is doubled after the clinical trial.

Zhang Chunming believes that Chinese medicine needs disruptive and transformative innovation to realize the "changing and overtaking" of the industry and the entire industry, and relying on artificial intelligence to build a "computational medicine" system is expected to take on the important task.

According to reports, the new drug digital research and development platform based on China Supercomputing was developed by the Institute of Computing Technology of the Chinese Academy of Sciences for 20 years.
During this period, it obtained the national "863" genomics data processing technology, the national "973" to establish a genetic data calculation model, and the Ministry of Science and Technology key research and development projects.
Support for national projects such as medical big data fusion model.